KNSA

SEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 4

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.

SEC source: 0001179110-20-010450 · edgar.xml · derivative · entry 8

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 502,896

Underlying: Class A Common Shares · 872 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 3

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013

Disclosed balance after: 211,900

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.

SEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 2

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.

SEC source: 0001179110-20-009723 · edgar.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Class A Common Shares · 180,000 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.

SEC source: 0001179110-20-009722 · edgar.xml · derivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Shares · 75,000 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.

SEC source: 0001179110-20-009721 · edgar.xml · derivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Shares · 50,000 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.

SEC source: 0001179110-20-009720 · edgar.xml · derivative · entry 1

Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Shares · 75,000 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.

SEC source: 0001179110-20-009719 · edgar.xml · derivative · entry 1

Megna Michael R · CIK 0001464583 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Class A Common Shares · 19,000 shares

Expires 2030-09-09

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.

SEC source: 0001179110-20-008544 · edgar.xml · derivative · entry 1

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,965

Underlying: Class A Common Shares · 37,965 shares

Expires 2030-07-26

F1 · derivative.exercise_date: The option vests and becomes exercisable as to one third of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a twenty-four month period thereafter. The vesting commencement date is July 27, 2020.

SEC source: 0001638599-20-000681 · doc4_6800.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,638,314

Underlying: Class A Common Shares · 1,335,362 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 93,210 and 1,335,362 Class A1 common shares ("Class A1 common shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $21.00 per share pursuant to a private placement with the Issuer that closed on July 24, 2020.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001638599-20-000681 · doc4_6800.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,143,650

Underlying: Class A Common Shares · 93,210 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F2 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a 4.99% beneficial ownership limitation ("Beneficial Ownership Limitation"), convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders. The Beneficial Ownership Limitation may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 93,210 and 1,335,362 Class A1 common shares ("Class A1 common shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $21.00 per share pursuant to a private placement with the Issuer that closed on July 24, 2020.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

SEC source: 0001104659-20-080552 · a4.xml · nonDerivative · entry 2

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1plan executed by the reporting person on December 24, 2019.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.78 to $25.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price

SEC source: 0001104659-20-080552 · a4.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,855

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1plan executed by the reporting person on December 24, 2019.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $24.77 to $25.74. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price

SEC source: 0001638599-20-000648 · doc4_6787.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 37,520

Underlying: Class A Common Shares · 37,520 shares

Expires 2030-06-30

F1 · derivative.exercise_price: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on June 30, 2020, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $25.48 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.exercise_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on June 30, 2020, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $25.48 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · derivative.expiration_date: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on June 30, 2020, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $25.48 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F1 · ownership.nature: 18,760 non-qualified stock options ("Stock Options") exercisable solely into Class A common shares ("Class A Common Shares") of Kiniksa Pharmaceuticals, Ltd. (the "Issuer") each granted to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, a full time employee of Baker Bros. Advisors LP (the "Adviser") on June 30, 2020, pursuant to the Issuer's 2018 Incentive Award Plan. The Stock Options with a strike price of $25.48 vest in 12 equal monthly installments and expire 10 years from the date of grant. Felix J. Baker and Dr. Biggar serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F2 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as part of their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Class A Common Shares resulting from the exercise of Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Class A Common Shares received as a result of the exercise of Stock Options.

SEC source: 0001104659-20-080553 · a4.xml · derivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2030-06-29

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020.

SEC source: 0001104659-20-080549 · a4.xml · derivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2030-06-29

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020.

SEC source: 0001104659-20-080550 · a4.xml · derivative · entry 1

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2030-06-29

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020.

SEC source: 0001104659-20-080547 · a4.xml · derivative · entry 1

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2030-06-29

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020.

SEC source: 0001104659-20-080548 · a4.xml · derivative · entry 1

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,760

Underlying: Class A Common Shares · 18,760 shares

Expires 2030-06-29

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of grant. The date of grant is June 30, 2020.

SEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778

F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2020 to June 30, 2020. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

SEC source: 0001179110-20-007295 · edgar.xml · derivative · entry 3

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,189

Underlying: Class A Common Shares · 13,752 shares

Expires 2025-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

F3 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 125,941 Shares. 25% of such Shares vested and became exercisable on August 1, 2016, and 1/36 of the remainder of the Shares vested and became exercisable monthly thereafter.

SEC source: 0001179110-20-007295 · edgar.xml · nonDerivative · entry 2

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,589

F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.00 to $25.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-007295 · edgar.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

SEC source: 0001638599-20-000499 · doc4_6697.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,302,952

Underlying: Class A Common Shares · 1,465,603 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 134,397 and 1,465,603 Class A1 common shares of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $18.25 per share pursuant to a private placement with the Issuer that closed on May 18, 2020.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001638599-20-000499 · doc4_6697.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,050,440

Underlying: Class A Common Shares · 134,397 shares

Expires not disclosed

F2 · derivative.exercise_price: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.exercise_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.expiration_date: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F2 · derivative.underlying: Represents the Issuer's Class A1 common shares which are subject to a beneficial ownership limitation, convertible at the election of the holder on a 1 for 1 basis into Class A common shares. The Class A1 common shares have no expiration date. Each Class A1 common share automatically converts into one Class A common share upon transfer, except for transfers to or between affiliated holders.

F1 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") purchased 134,397 and 1,465,603 Class A1 common shares of Kiniksa Pharmaceuticals, Ltd. (the "Issuer"), respectively, for $18.25 per share pursuant to a private placement with the Issuer that closed on May 18, 2020.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

SEC source: 0001179110-20-005046 · edgar.xml · nonDerivative · entry 3

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,589

F1 · kind: The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.12 to $20.60. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-005046 · edgar.xml · nonDerivative · entry 2

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,544

F1 · kind: The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.07 to $20.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-005046 · edgar.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,107

F1 · kind: The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.00 to $19.17. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-003836 · edgar.xml · derivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Class A Common Shares · 180,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.

SEC source: 0001179110-20-003835 · edgar.xml · derivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Shares · 75,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.

SEC source: 0001179110-20-003834 · edgar.xml · derivative · entry 1

Rizvi Qasim · CIK 0001794636 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Shares · 75,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.

SEC source: 0001179110-20-003833 · edgar.xml · derivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Shares · 50,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.

SEC source: 0001179110-20-003831 · edgar.xml · derivative · entry 1

Megna Michael R · CIK 0001464583 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Class A Common Shares · 17,000 shares

Expires 2030-03-12

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.

SEC source: 0001179110-20-003417 · edgar.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013

Disclosed balance after: 212,570

F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 6, 2019.

SEC source: 0001179110-20-002714 · edgar.xml · derivative · entry 2

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,574

Underlying: Class A Common Shares · 12,000 shares

Expires 2026-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested and became exercisable as to 25% of the total grant of 227,574 Class A Common Shares on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is August 15, 2016.

SEC source: 0001179110-20-002714 · edgar.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-20-002033 · edgar.xml · derivative · entry 7

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,542

Underlying: Class A Common Shares · 9,803 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F5 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.

SEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 5

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.31 to $19.37. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 4

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,116

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.30 to $19.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 3

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

SEC source: 0001179110-20-002033 · edgar.xml · derivative · entry 6

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,345

Underlying: Class A Common Shares · 22,477 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F5 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.

SEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 2

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.36. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-002033 · edgar.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

SEC source: 0001179110-20-001763 · edgar.xml · derivative · entry 6

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,822

Underlying: Class A Common Shares · 1,039 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F2 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.

SEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 4

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F4 · shares: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.26 to $18.47. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001179110-20-001763 · edgar.xml · nonDerivative · entry 3

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,039

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

SEC source: 0001179110-20-001872 · edgar.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · EVP & Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,530

F1 · kind: The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.

SEC source: 0001179110-20-001763 · edgar.xml · derivative · entry 5

Paolini John F. · CIK 0001741533 · SVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,861

Underlying: Class A Common Shares · 10,277 shares

Expires 2027-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Share Option exercise and sale of Class A Common Shares ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2019.

F2 · derivative.exercise_date: The Share Option granted the reporting person an option to purchase 110,138 Shares. 25% of such Shares vested and became exercisable on June 28, 2018, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.